First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled comparison with celecoxib [NCT00267215]

Cyclo-oxygenase-2 selective inhibitors are frequently used to manage osteoarthritis. We compared the analgesic efficacy of the novel cyclo-oxygenase-2 selective inhibitor lumiracoxib (Prexige(®)) versus placebo and celecoxib in patients with knee osteoarthritis. This seven day, double-blind, placebo...

Descripción completa

Detalles Bibliográficos
Autores principales: Wittenberg, Ralf H, Schell, Ernest, Krehan, Gerhard, Maeumbaed, Roland, Runge, Hans, Schlüter, Peter, Fashola, Taiwo OA, Thurston, Helen J, Burger, Klaus J, Trechsel, Ulrich
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1526611/
https://www.ncbi.nlm.nih.gov/pubmed/16469112
http://dx.doi.org/10.1186/ar1854

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1526611/
https://www.ncbi.nlm.nih.gov/pubmed/16469112
http://dx.doi.org/10.1186/ar1854

Ejemplares similares